Related Experiment Video
Updated: Jun 24, 2026
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Sankar D Navaneethan1, Vlado Perkovic, David W Johnson
1Department of Nephrology and Hypertension, Glickman Urological and Kidney institute, Cleveland Clinic, Cleveland, OH 44195, USA. navanes@ccf.org
Insights
Statins effectively lower cholesterol in kidney transplant recipients but do not significantly impact mortality. Further research is needed to confirm benefits for cardiovascular events and survival in this population.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is the leading cause of death in kidney transplant recipients, with dyslipidemia as a major contributing factor.
- Statins are commonly prescribed to manage dyslipidemia, but robust evidence supporting their efficacy in kidney transplant patients is limited.
Purpose of the Study:
- To evaluate the benefits and risks of statin therapy in kidney transplant recipients.
- To assess the impact of statins on mortality and kidney transplant outcomes.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
- Searches conducted across major databases including MEDLINE, EMBASE, and CENTRAL.
- Data extraction and quality assessment performed independently by two authors, with statistical analysis using random-effects models.
Main Results:
- Sixteen studies involving 3229 patients were included, comparing statins to placebo or other statins.
- Statins significantly reduced total cholesterol, LDL cholesterol, and triglycerides.
- No significant reduction in all-cause mortality was observed; however, trends favored statins for cardiovascular mortality and events, though not statistically significant. No significant difference in acute rejection risk was found.
Conclusions:
- Statins effectively manage hyperlipidemia in kidney transplant recipients and show a trend towards reducing cardiovascular events.
- Current evidence does not demonstrate a significant effect on mortality outcomes in this patient group.
- Given the established benefits in other populations, further studies are warranted to clarify the role of statins in kidney transplant recipients.
Background:
Cardiovascular deaths account for the majority of deaths in kidney transplant recipients and dyslipidaemia contributes significantly to their cardiovascular disease. Statins are widely used in kidney transplant patients given their established benefits in the general population, however evidence favouring their use is lacking.
Objectives:
To assess the benefits and harms of statin therapy on mortality and renal outcomes in kidney transplant recipients.
Search Strategy:
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and hand searched reference lists of articles and scientific proceedings.
Selection Criteria:
Randomised controlled trials (RCTs) and quasi-RCTs comparing statins with placebo, no treatment or other statins in kidney transplant recipients.
Data Collection And Analysis:
Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random effects model after testing for heterogeneity. Results were expressed as mean difference (MD) for continuous outcomes (lipid parameters) and risk ratio (RR) for dichotomous outcomes (mortality, allograft rejection, liver enzymes, occurrence of rhabdomyolysis and study withdrawal) with 95% confidence intervals (CI).
Main Results:
Sixteen studies (3229 patients) comparing statins versus placebo (15) or another statin (1) were included. Compared to placebo, statins did not decrease all-cause mortality (14 studies: RR 1.30, 95% CI 0.54 to 3.12). Point estimates favoured statins in terms of cardiovascular mortality (13 studies: RR 0.68, 95% CI 0.46 to 1.03) and non-fatal cardiovascular events (1 study: RR 0.70, 95% CI 0.48 to 1.01), however the results were not statistically significant. Compared to placebo, the use of statins was associated with a significantly lower end of treatment average total cholesterol (10 studies: MD -42.33 mg/dL (1.26 mmol/L), 95% CI -53.02 to -31.64), LDL cholesterol (10 studies: MD -46.15 mg/dL (1.19 mmol/L), 95% CI -55.97 to -36.33) and triglycerides (10 studies: MD -25.46 mg/dL (0.26 mmol/L), 95% CI -33.95 to 16.9). There was no significant difference in the risk of acute rejection (5 studies: RR 0.61; 95% C.I.0.32 to 1.16.) No data on chronic rejection was available and no major toxicity was noted.
Authors' Conclusions:
Statins significantly reduced hyperlipidaemia and tended to reduce cardiovascular events in kidney transplant recipients, but no effect has yet been demonstrated for mortality outcomes. Most of the data was derived from one large long-term study. Considering the significant impact of statins on all-cause and cardiovascular mortality in the general and predialysis populations, more studies are needed in kidney transplant patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Pharmacogenomics: Identification of New Drug Targets